Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Low μ-Opioid Receptor Status in Alcohol Dependence Identified by Combined Positron Emission Tomography and Post-Mortem Brain Analysis.

Hermann D, Hirth N, Reimold M, Batra A, Smolka MN, Hoffmann S, Kiefer F, Noori HR, Sommer WH, Reischl G, la Fougère C, Mann K, Spanagel R, Hansson AC.

Neuropsychopharmacology. 2017 Feb;42(3):606-614. doi: 10.1038/npp.2016.145. Epub 2016 Aug 11.

PMID:
27510425
2.

Experimental psychopathology paradigms for alcohol use disorders: Applications for translational research.

Bujarski S, Ray LA.

Behav Res Ther. 2016 Nov;86:11-22. doi: 10.1016/j.brat.2016.05.008. Epub 2016 May 28.

PMID:
27266992
3.

Converging findings from linkage and association analyses on susceptibility genes for smoking and other addictions.

Yang J, Li MD.

Mol Psychiatry. 2016 Aug;21(8):992-1008. doi: 10.1038/mp.2016.67. Epub 2016 May 10.

4.

Opioid Antagonists and the A118G Polymorphism in the μ-Opioid Receptor Gene: Effects of GSK1521498 and Naltrexone in Healthy Drinkers Stratified by OPRM1 Genotype.

Ziauddeen H, Nestor LJ, Subramaniam N, Dodds C, Nathan PJ, Miller SR, Sarai BK, Maltby K, Fernando D, Warren L, Hosking LK, Waterworth D, Korzeniowska A, Win B, Richards DB, Vasist Johnson L, Fletcher PC, Bullmore ET.

Neuropsychopharmacology. 2016 Oct;41(11):2647-57. doi: 10.1038/npp.2016.60. Epub 2016 Apr 25.

5.

A prospective study of genetic factors, human laboratory phenotypes, and heavy drinking in late adolescence.

Hendershot CS, Wardell JD, McPhee MD, Ramchandani VA.

Addict Biol. 2016 Apr 5. doi: 10.1111/adb.12397. [Epub ahead of print]

PMID:
27046326
6.

Convergent evidence from alcohol-dependent humans and rats for a hyperdopaminergic state in protracted abstinence.

Hirth N, Meinhardt MW, Noori HR, Salgado H, Torres-Ramirez O, Uhrig S, Broccoli L, Vengeliene V, Roßmanith M, Perreau-Lenz S, Köhr G, Sommer WH, Spanagel R, Hansson AC.

Proc Natl Acad Sci U S A. 2016 Mar 15;113(11):3024-9. doi: 10.1073/pnas.1506012113. Epub 2016 Feb 22.

7.

Differences in IV alcohol-induced dopamine release in the ventral striatum of social drinkers and nontreatment-seeking alcoholics.

Yoder KK, Albrecht DS, Dzemidzic M, Normandin MD, Federici LM, Graves T, Herring CM, Hile KL, Walters JW, Liang T, Plawecki MH, O'Connor S, Kareken DA.

Drug Alcohol Depend. 2016 Mar 1;160:163-9. doi: 10.1016/j.drugalcdep.2016.01.001. Epub 2016 Jan 13.

8.

Addictions Neuroclinical Assessment: A Neuroscience-Based Framework for Addictive Disorders.

Kwako LE, Momenan R, Litten RZ, Koob GF, Goldman D.

Biol Psychiatry. 2016 Aug 1;80(3):179-89. doi: 10.1016/j.biopsych.2015.10.024. Epub 2015 Nov 17. Review.

9.

Striatal dopaminergic reward response relates to age of first drunkenness and feedback response in at-risk youth.

Weiland BJ, Zucker RA, Zubieta JK, Heitzeg MM.

Addict Biol. 2017 Mar;22(2):502-512. doi: 10.1111/adb.12341. Epub 2016 Jan 5.

PMID:
26732626
10.

Morphine-induced antinociception and reward in "humanized" mice expressing the mu opioid receptor A118G polymorphism.

Henderson-Redmond AN, Yuill MB, Lowe TE, Kline AM, Zee ML, Guindon J, Morgan DJ.

Brain Res Bull. 2016 May;123:5-12. doi: 10.1016/j.brainresbull.2015.10.007. Epub 2015 Oct 28.

PMID:
26521067
11.

Association of the OPRM1 Variant rs1799971 (A118G) with Non-Specific Liability to Substance Dependence in a Collaborative de novo Meta-Analysis of European-Ancestry Cohorts.

Schwantes-An TH, Zhang J, Chen LS, Hartz SM, Culverhouse RC, Chen X, Coon H, Frank J, Kamens HM, Konte B, Kovanen L, Latvala A, Legrand LN, Maher BS, Melroy WE, Nelson EC, Reid MW, Robinson JD, Shen PH, Yang BZ, Andrews JA, Aveyard P, Beltcheva O, Brown SA, Cannon DS, Cichon S, Corley RP, Dahmen N, Degenhardt L, Foroud T, Gaebel W, Giegling I, Glatt SJ, Grucza RA, Hardin J, Hartmann AM, Heath AC, Herms S, Hodgkinson CA, Hoffmann P, Hops H, Huizinga D, Ising M, Johnson EO, Johnstone E, Kaneva RP, Kendler KS, Kiefer F, Kranzler HR, Krauter KS, Levran O, Lucae S, Lynskey MT, Maier W, Mann K, Martin NG, Mattheisen M, Montgomery GW, Müller-Myhsok B, Murphy MF, Neale MC, Nikolov MA, Nishita D, Nöthen MM, Nurnberger J, Partonen T, Pergadia ML, Reynolds M, Ridinger M, Rose RJ, Rouvinen-Lagerström N, Scherbaum N, Schmäl C, Soyka M, Stallings MC, Steffens M, Treutlein J, Tsuang M, Wall TL, Wodarz N, Yuferov V, Zill P, Bergen AW, Chen J, Cinciripini PM, Edenberg HJ, Ehringer MA, Ferrell RE, Gelernter J, Goldman D, Hewitt JK, Hopfer CJ, Iacono WG, Kaprio J, Kreek MJ, Kremensky IM, Madden PA, McGue M, Munafò MR, Philibert RA, Rietschel M, Roy A, Rujescu D, Saarikoski ST, Swan GE, Todorov AA, Vanyukov MM, Weiss RB, Bierut LJ, Saccone NL.

Behav Genet. 2016 Mar;46(2):151-69. doi: 10.1007/s10519-015-9737-3. Epub 2015 Sep 21.

12.

Mouse model of OPRM1 (A118G) polymorphism has altered hippocampal function.

Mague SD, Port RG, McMullen ME, Carlson GC, Turner JR.

Neuropharmacology. 2015 Oct;97:426-35. doi: 10.1016/j.neuropharm.2015.04.032. Epub 2015 May 15.

13.

In Vivo Monitoring of Dopamine by Microdialysis with 1 min Temporal Resolution Using Online Capillary Liquid Chromatography with Electrochemical Detection.

Gu H, Varner EL, Groskreutz SR, Michael AC, Weber SG.

Anal Chem. 2015 Jun 16;87(12):6088-94. doi: 10.1021/acs.analchem.5b00633. Epub 2015 May 26.

14.

GIRK3 gates activation of the mesolimbic dopaminergic pathway by ethanol.

Herman MA, Sidhu H, Stouffer DG, Kreifeldt M, Le D, Cates-Gatto C, Munoz MB, Roberts AJ, Parsons LH, Roberto M, Wickman K, Slesinger PA, Contet C.

Proc Natl Acad Sci U S A. 2015 Jun 2;112(22):7091-6. doi: 10.1073/pnas.1416146112. Epub 2015 May 11.

15.

Receptor Reserve Moderates Mesolimbic Responses to Opioids in a Humanized Mouse Model of the OPRM1 A118G Polymorphism.

Robinson JE, Vardy E, DiBerto JF, Chefer VI, White KL, Fish EW, Chen M, Gigante E, Krouse MC, Sun H, Thorsell A, Roth BL, Heilig M, Malanga CJ.

Neuropsychopharmacology. 2015 Oct;40(11):2614-22. doi: 10.1038/npp.2015.109. Epub 2015 Apr 16.

16.

Challenges and exciting new opportunities to advance personalized treatment for alcohol use disorder.

Becker HC.

Alcohol Clin Exp Res. 2015 Apr;39(4):587-8. doi: 10.1111/acer.12664. No abstract available.

17.

Impact of prospectively determined A118G polymorphism on treatment response to injectable naltrexone among methamphetamine-dependent patients: an open-label, pilot study.

Pal R, Mendelson JE, Flower K, Garrison K, Yount G, Coyle JR, Galloway GP.

J Addict Med. 2015 Mar-Apr;9(2):130-5. doi: 10.1097/ADM.0000000000000107.

18.

Regional brain [(11)C]carfentanil binding following tobacco smoking.

Domino EF, Hirasawa-Fujita M, Ni L, Guthrie SK, Zubieta JK.

Prog Neuropsychopharmacol Biol Psychiatry. 2015 Jun 3;59:100-4. doi: 10.1016/j.pnpbp.2015.01.007. Epub 2015 Jan 15.

19.

Effects of naltrexone on neural and subjective response to alcohol in treatment-seeking alcohol-dependent patients.

Spagnolo PA, Ramchandani VA, Schwandt ML, Zhang L, Blaine SK, Usala JM, Diamond KA, Phillips MJ, George DT, Momenan R, Heilig M.

Alcohol Clin Exp Res. 2014 Dec;38(12):3024-32. doi: 10.1111/acer.12581.

20.

Convergent functional genomics in addiction research - a translational approach to study candidate genes and gene networks.

Spanagel R.

In Silico Pharmacol. 2013 Dec 13;1:18. doi: 10.1186/2193-9616-1-18. eCollection 2013. Review.

Supplemental Content

Support Center